ReviewBioengineering & translational medicine2022
Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.
Review in Bioengineering & translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges.International journal of molecular sciences · 2026Pooled it
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- Exosome-loaded nanoradiosensitizers in radiotherapy for preventing post-irradiation tumor recurrence: mechanisms, preclinical evidence, and translational challenges.Discover nano · 2026Review
- Mechanistic trends and therapeutic targets in Radiation-Induced apoptosis: A bibliometric and translational mapping.Radiation and environmental biophysics · 2026Review
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Microenvironmental remodeling in FLASH radiotherapy.Frontiers in cell and developmental biology · 2026Review
- Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges.International journal of nanomedicine · 2026Review
- Multiplex Evaluation of Biointerface-Targeting Abilities and Affinity of Synthetized Nanoparticles-A Step Towards Improved Nanoplatforms for Biomedical Applications.Molecules (Basel, Switzerland) · 2024Article
- Enhancing Proton Radiosensitivity of Chondrosarcoma Using Nanoparticle-Based Drug Delivery Approaches: A Comparative Study of High- and Low-Energy Protons.International journal of molecular sciences · 2024Article
- Particle Beam Radiobiology Status and Challenges: A PTCOG Radiobiology Subcommittee Report.International journal of particle therapy · 2024Review
- Sarcoma cell-specific radiation sensitization by titanate scrolled nanosheets: insights from physicochemical analysis and transcriptomic profiling.Scientific reports · 2024Article
- Article
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- An Experimental Model of Proton-Beam-Induced Radiation Dermatitis In Vivo.International journal of molecular sciences · 2023Article
- Facile preparation of silver based radiosensitizers via biomineralization method for enhanced in vivo breast cancer radiotherapy.Scientific reports · 2023Article
- Red, green, and blue radio-luminescent polymer dots doped with heteroleptic tris-cyclometalated iridium complexes.RSC advances · 2023Article
- Recent Advances in Metal-Based NanoEnhancers for Particle Therapy.Nanomaterials (Basel, Switzerland) · 2023Review
- Review
- Advances in the Mechanistic Understanding of Iron Oxide Nanoparticles' Radiosensitizing Properties.Nanomaterials (Basel, Switzerland) · 2023Article
- Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving the efficacy and spatial targeting of radiation therapy while sparing surrounding normal tissues has been a guiding principle for its use in cancer therapy. Nanotechnologies have shown considerable growth in terms of innovation and the development of new therapeutic approaches, particularly as radiosensitizers. The aim of this study was to systematically review how nanoparticles (NPs) are used to enhance the radiotherapeutic effect, including preclinical and clinical studies. Clinicaltrials.gov was used to perform the search using the following terms: radiation, cancer, and NPs. In this review, we describe the various designs of nano-radioenhancers, the rationale for using such technology, as well as their chemical and biological effects. Human trials are then discussed with an emphasis on their design and detailed clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.